decorative shape
patient advocacy strategies icon

Blog Post

Published September 2, 2026
Patient Advocacy and Engagement

The Cost of Convenience: Why Administrative Hurdles Should Never Block Newborn Screening

patient advocacy strategies logo

Patient Advocacy and Engagement

In policy meetings and committee rooms across the country, newborn screening conditions are regularly scored, debated, and weighed. Leaders evaluate analytical validity, treatment efficacy, and system capacity.

But every so often, the conversation veers into a dangerous gray area: burden.

We hear concerns about the “burden” placed on families who may have to travel out of state for specialized care. We also hear about the headaches of navigating cross-border Medicaid reimbursements. In addition, there is administrative inconvenience to state programs and health systems when specialized infrastructure isn’t immediately available locally.

Logistical friction is a policy challenge we can solve. The preventable loss of a child is a tragedy no family ever recovers from.

The False Premise of Systemic Burden

When a scoring rubric or committee debate penalizes a rare condition because treatment is concentrated at a regional center or across the country, it prioritizes administrative ease over a child’s life.

It suggests that if a family has to figure out transportation, or if a state program has to coordinate out-of-state payment pathways, the screen itself might not be worth adding to the panel.

That is a fundamental breakdown of ethical duty.

  • Out-of-state travel is a logistical burden.
  • Complex reimbursement is an administrative headache.
  • Building clinical capacity requires time and effort.

However, none of these hurdles compare to the irreversible reality of a late or missed diagnosis.

When we frame administrative friction as a reason to delay or deny screening, we elevate state convenience above infant health.

Information Is Always Empowering

There is a related, equally paternalistic argument that sometimes surfaces in these debates: the idea that if a treatment is complex, distant, or costly, we shouldn’t burden parents with diagnostic knowledge.

That reasoning is deeply flawed. Families have an absolute right to diagnostic clarity about their child’s health. Knowing what a child is facing allows parents to advocate, seek specialized care, plan ahead, and make informed choices. Denying a diagnosis under the guise of “sparing” a family logistical stress isn’t protection—it’s deprivation.

The child will develop the disease regardless of when the family learns about it. However, empowering them with the knowledge needed to act matters greatly.

A Duty to Lead, Not Deflect

Newborn screening was never meant to be a static system designed for administrative ease. It is a lifesaving public health safety net.

It’s true: public health programs across the country are chronically under-resourced, understaffed, and asked to do more with less every single year. The hurdles states face—from tight budgets and outdated laboratory equipment to workforce shortages—are real. They are also persistent, and exhausting.

Acknowledging those constraints is necessary. Using them as a permanent justification for inaction is not.

As I lay out in A Brighter Blueprint, systems naturally default to inertia and administrative preservation unless we intentionally build pathways through them. When a system accepts its own limitations as an unchangeable reality, “we don’t have the resources” becomes a default shield against progress.

If the current framework cannot accommodate lifesaving advancements in screening, the solution isn’t to hold back science or leave children diagnosed too late. The solution is to change the framework.

We have to ask ourselves a fundamental question: Do we allow operational hurdles to dictate what is possible, or do we find creative, relentless ways to solve them?


Public health leadership requires moving past deflection and toward innovation:

  • Leveraging regional partnerships and multi-state laboratory consortiums to share testing capacity and reduce individual state costs.
  • Modernizing fee structures annually so programs can directly fund the infrastructure required for new condition additions.
  • Coordinating with advocacy coalitions and health systems to build out-of-state referral networks and patient travel funds. This is better than treating geography as a barrier to care.

Underfunded systems need real support, honest funding, and legislative backing—not excuses. If a test can identify a treatable condition before irreversible harm occurs, our duty is clear: we fight for the resources, build the capacity, and fix the system.

Because when the stakes are a child’s life, “it’s too difficult” is never an acceptable answer.

Lesa Brackbill

About the Author
Lesa Brackbill is the Director of Advocacy for Patient Advocacy Strategies. She has ten years of experience in rare disease advocacy and successfully changed two Newborn Screening laws in Pennsylvania to increase access to timely diagnosis and treatment for babies with rare diseases. Lesa is passionate about strategic communication and effective advocacy. She and her family live in Hershey, Pennsylvania. Learn more about Lesa’s work here.
Learn more about Lesa Brackbill
patient advocacy strategies icon
search...